delandistrogene moxeparvovec clinical trials
3 indexed studies · 1 currently recruiting
- Active not recruitingPHASE2
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
This study looks at a new gene therapy called delandistrogene moxeparvovec for boys with Duchenne Muscular Dystrophy (DMD) under four years old. It checks how safe it is and if it helps the body make a missing protein.
For: Duchenne Muscular DystrophyBelgium · France · Germany - Enrolling by invitationPHASE3
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
This study is checking how people who previously received a treatment called delandistrogene moxeparvovec for Duchenne muscular dystrophy are doing over time. Researchers want to see if the treatment is safe and effective in the long run. No new treatment will be given during this study.
For: Duchenne Muscular DystrophyUnited States · Belgium · Germany - Active not recruitingPHASE3
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
This study is testing a new gene therapy called delandistrogene moxeparvovec for boys with Duchenne Muscular Dystrophy (DMD). It aims to see if it's safe and effective for those who can and cannot walk. Some boys will receive the treatment, others a dummy treatment.
For: Duchenne Muscular DystrophyUnited States · Australia · Belgium